Chi Siamo
G. R. represents the natural continuity of Abiogen Pharma’s R&D activity started in 1997 and maintains both the Research Centre structure in Migliarino and the entire group of researchers. Moreover, in order to more adequately deal with the constant transformations of the pharmaceutical R&D sector and the identification of the best strategies for scientific development and corporate management, a high expertise board of directors has been appointed among which a selected CEO with full autonomy in his role at Galileo Research.
The GLP certified Abiogen Pharma Research Centre - Testing Facility has extensive experience in research and preclinical development and is particularly skilled in animal toxicology, genotoxicity, ADME and in vivo models of diseases to test treatment efficacy, and has strong knowledge in in vitro gene expression profiling, RT-PCR, recombinant protein expression, monoclonal antibody preparation, 2-D electrophoresis and other advanced technologies. A small organic chemistry laboratory is involved in rational drug design and medicinal chemistry, and the development of synthetic processing in industrial scale-up.
The Research Centre boasts a wide and active network of experience and expertise with a number of scientific laboratories in Tuscany where Galileo’s projects can also benefit from the extensive knowledge and excellence of the Territory.
All the studies at the Galileo Research Centre are performed according to ICH, OECD, REACH guidelines, in full compliance with the Good Laboratory Practice (GLP) regulations (certified by the Italian Health Authorities since 1990) and supervised by an external Quality Assurance Service.